Skip to content

Home
Company
Science
- Evorpacept
- Publications
Pipeline
- Clinical Trials
- Expanded
  Access Policy
Careers
- Current Jobs
Investors
Contact

Targeting the Myeloid Checkpoint Receptor SIRPα Potentiates Innate and Adaptive Immune Responses to Promote Anti‑Tumor Activity

Post navigation

Previous: ALX148, a CD47 Blocker, in Combination with Standard Chemotherapy and Antibody Regimens in Patients with Gastric/Gastroesophageal Junction (GC) Cancer and Head and Neck Squamous Cell Carcinoma (HNSCC); ASPEN-01

Next: ALX148 Enhances the Depth and Durability of Response to Multiple AML Therapies

Home
Company
Science
- Evorpacept
- Publications
Pipeline
- Clinical Trials
- Expanded
  Access Policy
Careers
- Current Jobs
Investors
Contact

© ALX Oncology Inc., All rights reserved.
Privacy Policy Twitter LinkedIn Level Access